Cany Jeannette, van der Waart Anniek B, Spanholtz Jan, Tordoir Marleen, Jansen Joop H, van der Voort Robbert, Schaap Nicolaas M, Dolstra Harry
Department of Laboratory Medicine; Laboratory of Hematology; Radboud University Medical Center (Radboudumc); Nijmegen, The Netherlands.
Glycostem Therapeutics; 's-Hertogenbosch , The Netherlands.
Oncoimmunology. 2015 Apr 1;4(7):e1017701. doi: 10.1080/2162402X.2015.1017701. eCollection 2015 Jul.
Adoptive transfer of allogeneic natural killer (NK) cells represents a promising treatment approach against cancer, including acute myeloid leukemia (AML). Previously, we reported a cytokine-based culture method for the generation of NK cell products with high cell number and purity. In this system, CD34 hematopoietic progenitor cells (HPC) were expanded and differentiated into NK cells under stroma-free conditions in the presence of IL-15 and IL-2. We show that combining IL-15 with IL-12 drives the generation of more mature and highly functional NK cells. In particular, replacement of IL-2 by IL-12 enhanced the cytolytic activity and IFNγ production of HPC-NK cells toward cultured and primary AML cells , and improved antileukemic responses in NOD/SCID-IL2Rγnull (NSG) mice bearing human AML cells. Phenotypically, IL-12 increased the frequency of HPC-NK cells expressing NKG2A and killer immunoglobulin-like receptor (KIR), which were more responsive to target cell stimulation. In addition, NK15/12 cell products demonstrated superior maturation potential, resulting in >70% positivity for CD16 and/or KIR within 2 weeks after infusion into NSG mice. We predict that higher functionality and faster maturation will favor HPC-NK cell alloreactivity toward malignant cells in patients, making this cytokine combination an attractive strategy to generate clinical HPC-NK cell products for cancer adoptive immunotherapy.
同种异体自然杀伤(NK)细胞的过继性转移是一种很有前景的癌症治疗方法,包括急性髓系白血病(AML)。此前,我们报道了一种基于细胞因子的培养方法,用于生成细胞数量多且纯度高的NK细胞产品。在该系统中,CD34造血祖细胞(HPC)在无基质条件下,于白细胞介素-15(IL-15)和白细胞介素-2(IL-2)存在的情况下进行扩增并分化为NK细胞。我们发现,将IL-15与IL-12联合使用可驱动生成更成熟且功能更强的NK细胞。特别是,用IL-12替代IL-2可增强HPC-NK细胞对培养的和原发性AML细胞的细胞溶解活性及γ干扰素(IFNγ)产生,并改善在携带人AML细胞的NOD/SCID-IL2Rγ基因敲除(NSG)小鼠中的抗白血病反应。从表型上看,IL-12增加了表达NKG2A和杀伤细胞免疫球蛋白样受体(KIR)的HPC-NK细胞的频率,这些细胞对靶细胞刺激反应更强。此外,NK15/12细胞产品表现出卓越的成熟潜力,在注入NSG小鼠后2周内,CD16和/或KIR阳性率>70%。我们预测,更高的功能和更快的成熟将有利于HPC-NK细胞对患者恶性细胞的同种异体反应性,使这种细胞因子组合成为一种有吸引力的策略,可用于生成用于癌症过继性免疫治疗的临床HPC-NK细胞产品。